Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan.
Tsubasa TsutsumiTakumi KawaguchiHideki FujiiYoshihiro KamadaHirokazu TakahashiMiwa KawanakaYoshio SumidaMichihiro IwakiHideki HayashiHidenori ToyodaSatoshi OedaHideyuki HyogoAsahiro MorishitaKensuke MunekageKazuhito KawataKoji SawadaTatsuji MaeshiroHiroshi TobitaYuichi YoshidaMasafumi NaitoAsuka ArakiShingo ArakakiHidenao NoritakeMasafumi OnoTsutomu MasakiSatoshi YasudaEiichi TomitaMasato YonedaAkihiro TokushigeShinichiro UedaShinichi AishimaHirokazu TakahashiTakeshi OkanouePublished in: Alimentary pharmacology & therapeutics (2024)
In patients with biopsy-proven MASLD, the prevalence of MASH and advanced fibrosis was approximately 65% and 20%, respectively. The leading cause of mortality was liver-related events. Hepatic inflammation and fibrosis were significant factors influencing mid-term mortality. These findings highlight the importance of targeting inflammation and fibrosis in the management of patients with MASLD.